Skip to main content

Xembify FDA Approval History

Last updated by Judith Stewart, BPharm on Aug 3, 2020.

FDA Approved: Yes (First approved July 3, 2019)
Brand name: Xembify
Generic name: immune globulin subcutaneous, human - klhw
Dosage form: Injection
Company: Grifols
Treatment for: Primary Immunodeficiency Syndrome

Xembify (immune globulin subcutaneous, human- klhw) is a 20% immune globulin solution for subcutaneous injection indicated for treatment of Primary Humoral Immunodeficiency (PI).

Development Timeline for Xembify

DateArticle
Jul  4, 2019Approval  FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.